SEARCH:
Print

Board of Directors

The Board consists of six external members elected by the shareholders at the annual general meeting for terms of one year; retiring members are eligible for re-election.

Target figure for the underrepresented gender.

Members of the board of directors

Gerard van Odijk, M.D.

Gerard van Odijk, M.D.

Independent member of the board since 2008 and chairman since 2014. Current term expires in 2019. Chairman of the Nomination and Compensation Committee since 2015.

Dr. van Odijk is a Dutch national, born in 1957.

Positions: Independent advisor for the pharmaceutical industry and former president and chief executive officer of Teva Pharmaceuticals Europe B.V. Chairman of the board of HTL-Strefa S.A. and Curaeos B.V.

Special competences: Medical qualifications and extensive executive background within publicly traded and private companies in the international healthcare.

Anders Gersel Pedersen, M.D., Ph.D.

Anders Gersel Pedersen, M.D., Ph.D.

Independent member of the board since 2010 and deputy chairman since 2014. Current term expires in 2019. Member of the Finance, Risk and Audit Committee since 2015.

Dr. Pedersen is a Danish national, born in 1951.

Positions: Former executive vice president of research and development at H. Lundbeck A/S. Member of the board of Genmab A/S and Hansa Biopharma AB. 

Special competences: Scientific qualifications, particularly in oncology, and extensive board and management experience from publicly traded, international pharmaceutical and biotech industries.

Erik G. Hansen, M.Sc.

Erik G. Hansen, M.Sc.

Independent member of the board since 2010. Current term expires in 2019. Chairman of the Finance, Risk and Audit Committee since 2015.

Mr. Hansen is a Danish national, born in 1952.

Positions: Chairman of the board of Polaris Management A/S, TTiT A/S, TTiT Ejendomme A/S, TTiT Landbrug A/S and Sirius Holding ApS. Deputy chairman of the board of Okono A/S, Lauritzen Fonden and Bagger-Sørensen & Co. A/S and its five subsidiaries, member of the board of Bagger-Sørensen Fonden, Saga Private Equity ApS, Lesanco ApS, Ecco Sko A/S, Farumgade 2B Holding ApS and its subsidiary and Wide Invest ApS. Member of the executive board of Rigas Invest ApS, BFB ApS, Haslevej 3 ApS, Sirius Holding ApS, Tresor Asset Advisers ApS, Polaris Invest II ApS and Hansen Advisers ApS.

Special competences: Training and experience in and thorough understanding of managing finance operations and experience with publicly traded companies.

Peter Kürstein, MBA

Peter Kürstein, MBA

Independent member of the board since 2012. Current term expires in 2019. Member of the Nomination and Compensation Committee since 2015.

Mr. Kürstein is a Danish national, born in 1956.

Former president and chief executive officer, now chairman of the board of Radiometer Medical ApS. Chairman of the board of Ferrosan Medical Devices Holding A/S. Deputy chairman of the board of FOSS A/S, Experimentarium and Ejendomsselskabet Experimentarium A/S. Member of the board of N. Foss & Co. A/S and Den Erhvervsdrivende Fond Gl. Strand, Experimentarium, One Life, Dansk BørneAstma Center and Art Agenda 2030. Chairman of the Business Forum for Better Regulation and vice chairman of the American Chamber of Commerce. Member of the executive board of Mijamax ApS.

Special competences: Extensive board and management experience from publicly traded, international healthcare companies.

Frank Verwiel, M.D.

Frank Verwiel, M.D.

Independent member of the board since 2016. Current term expires in 2019. Member of the Finance, Risk and Audit Committee since 2016.

Dr. Verwiel is a Dutch national, born in 1962.

Positions: Former President and CEO of Aptalis Pharma, Inc. Chairman of the board of ObsEva SA and member of the board of Intellia Therapeutics, Inc. and Achillion Pharmaceuticals, Inc.

Special competences: Extensive strategic, operational and international experience within the pharmaceutical industry.

Elizabeth McKee Anderson, MBA

Elizabeth McKee Anderson, MBA

Independent member of the board since 2017. Current term expires in 2019. Member of the Nomination and Compensation Committee since 2018.

Ms. Anderson is an American national, born in 1957.

Positions: Former worldwide vice president Global Strategic Marketing and Market Access, Infectious Diseases and Vaccines for Johnson&Johnson. Member of the board of Context Therapeutics LLC, Insmed, Inc., Huntsworth plc and REVOLUTION Medicines, Inc. and Aro Biotherapeutics Company and a member of the advisory Board of NAXION, Inc. Furthermore, she is a member of the board of trustees of the Bryn Mawr Hospital Foundation and The Wistar Institute. Principal of PureSight Advisory, LLC.

Special competences: Extensive strategic, operational and international experience within the pharmaceutical industry.